To the editor: We read with great interest the comments by Arena et al. and Chang in reference to our paper, 'Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance'. 1 Their letters focused on different issues of the HER2 intratumoral heterogeneity in breast cancer.
Arena et al. questioned about the best way to write HER2 reports for the clinician and suggested that HER2 analytical report should be completed with a critical evaluation of the results about HER2 genetic heterogeneity. Although the clinical relevance of HER2 genetic heterogeneity is not established in breast cancer, we agree that HER2 in situ hybridization report should include not only overall average ratio of HER2/CEP17 and average HER2 gene copy number, but also information about HER2 genetic heterogeneity. However, there are some issues to be addressed in the definition of HER2 genetic heterogeneity proposed by 2009 College of American Pathologists expert panel, which indicates the presence of tumor cells with HER2/CEP17 signal ratios 42.2 (or 46 HER2 signals per cell when using a probe for HER2 only) in 5-50% of the tumor cells tested. 2 If 20 cells are counted and 1 tumor cell is identified with a HER2/CEP17 42.2, the tumor is diagnosed to have HER2 genetic heterogeneity. However, a recent study revealed that the tumor cells with 3:1 HER2/CEP17 ratio, which may reflect technical issues, were determining factor for heterogeneity in 46% of heterogeneous cases. 3 Furthermore, Allison et al. 4 reported that the ratio criteria and the criteria based on HER2 signals per cell for definition of HER2 genetic heterogeneity were not equivalent and the ratio-based definition resulted in large numbers of non-amplified cases being classified as heterogeneous. Thus, to avoid artifactual heterogeneity caused by technical issues, such as nuclear truncation and inadequate hybridization, cutoff values of percentage and cell ratio for HER2 genetic heterogeneity need to be validated. Furthermore, the number of cells to be counted and the fields to be selected for counting should be clearly defined through robust evidence.
HER2 intratumoral heterogeneity appears as two forms; distinct clusters of amplified cells and admixture of amplified and non-amplified cells. Distinct HER2 amplified clones in a non-amplified tumor, which was defined as HER2 regional heterogeneity in our study, should be scored separately, as proposed previously. 2,5 HER2 regional heterogeneity can be assessed by scanning the entire tumor section before selection of fields to be counted and matching with HER2 immunohistochemistry (IHC). If the tumor has differentially amplified or stained area, the regions should be included in the counting. From this point of view, silver in situ hybridization has an advantage to evaluate HER2 regional heterogeneity, because it can be easily matched with HER2 IHC slide under light microscope. We agree to Arena et al. that detailed report of HER2 IHC is the simplest way to report HER2 regional heterogeneity. As shown in our study, heterogeneous HER2 expression was well matched with HER2 regional or genetic heterogeneity.
The main issue pointed out by Chang is the prognostic significance of HER2 intratumoral heterogeneity. He argued that the conflicting prognostic effect of HER2 intratumoral heterogeneity is related to patient treatment. We agree that different treatment may account for different outcome, as shown in the study by Bartlett et al. 5 For survival analysis, they used TEAM (Tamoxifen vs Exemestane adjuvant Multicentre) pathology study composed of estrogen receptor-positive early breast cancers, treated with adjuvant endocrine therapy (exemestane versus tamoxifen), but not with chemotherapy. 6 However, tumors with heterogeneous HER2 amplification cannot be equated with those with borderline/low HER2 amplification. Although HER2 genetic and regional heterogeneity was more common in tumors with equivocal/low-grade amplification, they were found in 23 and 38% of tumors with equivocal/lowgrade amplification in our study. Thus, comparison of our study with the HERA trial 7 is not reasonable. We admit that our study has a limitation for survival analysis due to small number of heterogeneous cases. Further large-scaled, well-designed studies will be needed to find clinically relevant definition of HER2 intratumoral heterogeneity and to establish its prognostic significance and predictive value for HER2 targeted therapy.
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